Recurrent hyperkalaemia management and use of renin–angiotensin–aldosterone system inhibitors: a European multi-national targeted chart review-Reference-Cited by-同舟云学术

Recurrent hyperkalaemia management and use of renin–angiotensin–aldosterone system inhibitors: a European multi-national targeted chart review

Published:2019-09-30 Issue:4 Volume:13 Page:714-719
ISSN:2048-8513
Container-title:Clinical Kidney Journal
language:en
Short-container-title:

Author:

Rossignol Patrick¹,Ruilope Luis M²,Cupisti Adamasco³,Ketteler Markus⁴⁵,Wheeler David C⁶,Pignot Marc⁷,Cornea Georgiana⁸,Schulmann Thierry⁸,Lund Lars H⁹¹⁰

Affiliation:

1. Université de Lorraine, Inserm, Centre d’Investigations Cliniques-Plurithématique 14-33, Inserm U116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France

2. Hypertension Unit, Instituto de Investigación imas12, Hospital Universitario, Madrid, Spain

3. Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

4. Department of General Internal Medicine and Nephrology, Robert-Bosch-Krankenhaus, Stuttgart, Germany

5. University of Split School of Medicine, Split, Croatia

6. Clinical Effectiveness Group, Centre for Primary Care and Public Health, Queen Mary University of London, London, UK

7. Kantar Health GmbH, Real World Research & Value, Munich, Germany

8. Vifor Pharma Group, Glattbrugg, Switzerland

9. Department of Medicine, Karolinska Institutet, Stockholm, Sweden

10. Karolinska University Hospital, Heart and Vascular Theme, Stockholm, Sweden

Funder

Vifor Pharma

Publisher

Oxford University Press (OUP)

Subject

Transplantation,Nephrology

Link

http://academic.oup.com/ckj/article-pdf/13/4/714/33871550/sfz129.pdf

Reference11 articles.

1. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes;Collins;Am J Nephrol,2017

2. New therapeutic approaches for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors;Tamargo;Cardiovasc Drugs Ther,2018

3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of chronic kidney disease;Kidney Int Suppl,2013

4. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS);N Engl J Med,1987

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Potassium Binders for CKD Patients with Hyperkalemia;Chronic Kidney Disease - Novel Insights into Pathophysiology and Treatment;2024-04-15

2. Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial;Diabetes, Obesity and Metabolism;2024-03-18

3. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial;The Lancet;2024-01

4. Economic impact of the use of patiromer in chronic kidney disease or heart failure for the treatment of chronic hyperkalemia in Spain;Nefrología (English Edition);2023-11

5. Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease;American Journal of Nephrology;2023-10-30